Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR).

Full DD Report for ARWR

You must become a subscriber to view this report.


Recent News from (NASDAQ: ARWR)

Wired News - Arrowhead Pharma Presented Preclinical Data on Expanding Pipeline of RNAi Therapeutics for Cardiometabolic Diseases
Stock Monitor: Aptevo Therapeutics Post Earnings Reporting LONDON, UK / ACCESSWIRE / May 15, 2018 / If you want access to our free research report on Arrowhead Pharma, Inc. (NASDAQ: ARWR ), all you need to do is sign up now by clicking the following link www.active-investors.com/regi...
Source: ACCESSWIRE IA
Date: May, 15 2018 07:40
Arrowhead Doses First Hepatitis B Patients in Multiple Dose Portion of Phase 1/2 Study of ARO-HBV
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has dosed the first 3 hepatitis B virus (HBV) patients in the multiple-ascending dose portion of its ongoing Phase 1/2 study of ARO-HBV, the company’s third generation subcutaneously administered RNA interference (R...
Source: Business Wire
Date: May, 14 2018 07:30
Arrowhead Pharmaceuticals Presents Preclinical Data on Expanding Cardiometabolic Pipeline
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced the presentation of new preclinical data on its expanding pipeline of RNA interference (RNAi) therapeutics for cardiometabolic diseases, including ARO-ANG3, which targets angiopoietin-like protein 3 (ANGPTL3), and ARO-APOC3, which...
Source: Business Wire
Date: May, 11 2018 07:30
Harry Boxers 5 Momentum Stocks Moving on Earnings Today
Here are five momentum stocks making a move primarily on earnings: Arrowhead Pharmaceuticals , Endocyte, Legacy Reserves, Impinj and PolarityTE , writes Harry Boxer Thursday. He is the founder of  TheTechTrader.com . Arrowhead Pharmaceuticals, Inc. ( ARWR ) jumped $1.2...
Source: MoneyShow.com
Date: May, 10 2018 09:31
Arrowhead Pharmaceuitcals Releases Quarterly Results - Shares Jump Over 10%
Shares of the California-based biotechnology company Arrowhead Pharmaceuticals (NASDAQ:ARWR) rose over 10% after the company released its second-quarter results of 2018. The company saw a decrease in revenue compared to the previous year, falling from $8.98 million USD to $650,125.00. ...
Source: MicroSmallCap
Date: May, 09 2018 19:19
Premarket Gainers as of 9:05 am (05/09/2018)
DCIX +69%  on Q1 result . More news on: Diana Containerships Inc., Qumu Corporation, TripAdvisor Inc., Stocks on the move, , Read more ...
Source: SeekingAlpha
Date: May, 09 2018 09:20
Recent Analysis Shows Extreme Networks, Lumber Liquidators, Owens-Illinois, Arrowhead Pharmaceuticals, Intrepid Potash, and General Cable Market Influences - Renewed Outlook, Key Drivers of Growth
NEW YORK, May 09, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Extreme Networks, Inc. (NASDAQ:EXTR), Lumber Liquidators Holdings, Inc (NY...
Source: GlobeNewswire
Date: May, 09 2018 08:00
Arrowhead Pharmaceuticals' (ARWR) CEO Christopher Anzalone on Fiscal Q2 2018 Results - Earnings Call Transcript
Arrowhead Pharmaceuticals, Inc. (ARWR) Q2 2018 Results Earnings Conference Call May 8, 2018, 04:30 PM ET Executives Vincent Anzalone - Vice President, Head of Investor Relations Christopher Anzalone - President and Chief Executive Officer Bruce Given - Chief Operating Officer K...
Source: SeekingAlpha
Date: May, 08 2018 23:05
Arrowhead Pharmaceuticals beats by $0.01, misses on revenue
Arrowhead Pharmaceuticals (NASDAQ: ARWR ): Q2 EPS of -$0.18 beats by $0.01 . More news on: Arrowhead Pharmaceuticals, Earnings news and commentary, Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: May, 08 2018 16:02
Arrowhead Pharmaceuticals Reports Fiscal 2018 Second Quarter Results
Conference Call and Webcast Today at 4:30 p.m. EDT Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2018 second quarter ended March 31, 2018. The company is hosting a conference call at 4:30 p.m. EDT to discuss results. Conference Call ...
Source: Business Wire
Date: May, 08 2018 16:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-05-179.499.539.829.44971,514
2017-06-201.651.631.681.60522,169
2017-06-191.591.651.671.55550,962
2017-06-161.641.591.681.55654,013
2017-06-151.601.681.691.58445,323

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-17199,318446,85044.6051Short
2018-08-16219,302458,09047.8731Short
2018-08-15388,049561,67969.0873Short
2018-08-14221,000405,84354.4546Short
2018-08-13207,323295,53570.1518Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on ARWR.


About Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR)

Logo for Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR)

Not available

 

Contact Information

 

 

Current Management

  • Christopher Anzalone / CEO
  • Joseph T. Kingsley / CFO
  • Ken Myszkowski / CFO

Current Share Structure

  • Market Cap: $817,538,872 - 05/14/2018
  • Issue and Outstanding: 86,787,566 - 02/07/2018

 


Recent Filings from (NASDAQ: ARWR)

Statement of beneficial ownership of common stock by certain persons
Filing Type: SC 13GFiling Source: edgar
Filing Date: May, 14 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 08 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 08 2018
Securities offered to employees under employee benefit plans
Filing Type: S-8Filing Source: edgar
Filing Date: March, 22 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 20 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: February, 09 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: February, 09 2018
Statement of beneficial ownership of common stock by certain persons
Filing Type: SC 13GFiling Source: edgar
Filing Date: February, 06 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: January, 25 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: January, 25 2018

 

 


Daily Technical Chart for (NASDAQ: ARWR)

Daily Technical Chart for (NASDAQ: ARWR)


Stay tuned for daily updates and more on (NASDAQ: ARWR)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: ARWR)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in ARWR is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of ARWR and does not buy, sell, or trade any shares of ARWR. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/